RecruitingPhase 2NCT04858334

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Studying Acinar cell carcinoma of pancreas

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Kim A Reiss Binder
ECOG-ACRIN Cancer Research Group
Intervention
Biospecimen Collection(procedure)
Enrollment
152 enrolled
Eligibility
18 years · All sexes
Timeline
20212027

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04858334 on ClinicalTrials.gov

Other trials for Acinar cell carcinoma of pancreas

Additional recruiting or active studies for the same condition.

See all trials for Acinar cell carcinoma of pancreas

← Back to all trials